UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with salvage surgery and radiation. This study will also determine what effects, good and/or bad, this drug has on the participants.
Head and Neck Cancer
DRUG: Erlotinib
Number of Participants Demonstrating the Safety and Tolerability of Long Term Erlotinib Treatment, Number of participants who had the most frequently observed undesirable effects after exposure to study drug, 12 - 24 months|Percentage of Participants With Disease Free Status at 12 Months and 24 Months, Percentage of participants who were disease free at 12 months (12 months after initiation of study drug treatment) and 24 months (12 months after completion of study drug treatment), 12 - 24 months
Percentage of Participants Demonstrating Survival at 12 Months and 24 Months., Percentage of participants who were still alive at 12 months following completion of study drug therapy and at 24 months following completion of study drug therapy, 12 - 24 months
An investigator-initiated Phase II clinical trial of the safety and tolerability of erlotinib as an adjuvant therapy after definitive therapy via salvage surgery in head and neck cancer patients.